Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > HIV lipodystrophy causes morbidity and mortality

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Dec 24, 2024 8:16am

65 Views

Post# 36376144

RE:RE:RE:RE:RE:RE:HIV lipodystrophy causes morbidity and mortality

"It's cash flow, debt, sales growth potential and the like."
How can they increase cash flow, reduce debt and improve sale growth potential?
Better revenues and cost control. In order to sell any product one has to convince and educate the customer about its benefits... enough said

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks